Literature DB >> 22183934

Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature.

S Jarius1, F Paul, D Franciotta, J de Seze, C Münch, M Salvetti, K Ruprecht, M Liebetrau, K P Wandinger, G Akman-Demir, A Melms, W Kristoferitsch, B Wildemann.   

Abstract

BACKGROUND: Neuromyelitis optica (NMO, Devic syndrome) and myasthenia gravis (MG) are rare antibody-mediated autoimmune disorders. Concurrent incidence has been reported in only few patients, mostly non-Caucasians.
OBJECTIVE: To report on ten Caucasian patients with NMO spectrum disorders (NMOSD) and MG and to provide a comprehensive review of the literature.
METHOD: Retrospective study.
RESULTS: In total, 26 patients (m:f = 1:12; Caucasian in 12) with MG (generalized in 17) and NMOSD (NMO in 21, longitudinally extensive transverse myelitis in five) were identified from the authors' own files (n = 10) and the previous literature (n = 16). MG preceded NMOSD in 24/25 cases (96%). AQP4-Ab were tested in 20 patients and were positive in 17 (85%). Twenty out of 25 patients (80%) had been treated with thymectomy or thymic irradiation, which preceded NMOSD in all cases (median latency, 12 years; range, 0.3-32). At last follow-up, complete remission of MG was reported in 15/22 (68%), and MG was well controlled with pyridostigmine in three. Co-existing autoimmune disorders or autoimmune antibodies were reported in 17 patients.
CONCLUSION: Our study demonstrates that i) AQP4-Ab-positive NMOSD are more commonly associated with MG in Caucasians than previously thought; ii) MG precedes NMOSD in most cases, often by more than a decade; iii) NMOSD almost exclusively occur in females with juvenile or early-onset MG; and iv) MG frequently takes an unusually mild course in patients with NMOSD. A history of thymectomy could be a possible risk factor for the later development of NMOSD. We recommend testing for AQP4-Ab in MG patients presenting with atypical motor or optic symptoms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22183934     DOI: 10.1177/1352458511431728

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  39 in total

Review 1.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

Review 2.  [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].

Authors:  Orhan Aktas; Tania Kümpfel
Journal:  Nervenarzt       Date:  2021-03-16       Impact factor: 1.214

Review 3.  Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.

Authors:  Eduardo Freitas; Joana Guimarães
Journal:  Rheumatol Int       Date:  2014-06-22       Impact factor: 2.631

4.  Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.

Authors:  S Jarius; F Paul; K Ruprecht; B Wildemann
Journal:  J Neurol       Date:  2012-09-28       Impact factor: 4.849

5.  Neuromyelitis Optica Spectrum Disorder in a Chinese Woman with Ocular Myasthenia Gravis: First Reported Case in the Chinese Population.

Authors:  Gordon S K Yau; Jacky W Y Lee; Theo T K Chan; Can Y F Yuen
Journal:  Neuroophthalmology       Date:  2014-04-02

6.  Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.

Authors:  Julien Ratelade; Alex J Smith; A S Verkman
Journal:  Exp Neurol       Date:  2014-03-14       Impact factor: 5.330

Review 7.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 8.  Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD).

Authors:  Diego Franciotta; Matteo Gastaldi; Arianna Sala; Francesca Andreetta; Elena Rinaldi; Maddalena Ruggieri; Rosaria Leante; Gianna Costa; Tiziana Biagioli; Luca Massacesi; Elena Bazzigaluppi; Raffaella Fazio; Sara Mariotto; Sergio Ferrari; Elisabetta Galloni; Francesco Perini; Elisabetta Zardini; Luigi Zuliani; Marco Zoccarato; Bruno Giometto; Antonio Bertolotto
Journal:  Neurol Sci       Date:  2017-10       Impact factor: 3.307

9.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

10.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.